A rteriosclerosis in the transplanted heart is an accelerated process that is the most important limiting factor in the long-term survival of cardiac transplant patients. It is a diffuse, concentric process affecting both large and small coronary vessels12 and is difficult to detect by conventional angiography or noninvasive techniques.
Accelerated transplant arteriosclerosis leads to occlusive vascular changes and subsequent ischemic myocardial damage, as does atherosclerotic coronary artery disease. However, small-vessel disease is more prominent in the transplanted heart. These small intramyocardial vessels have vasomotor regulatory control over coronary blood flow. Dystrophic or dysfunctional changes in these crucial sites of regulation may compro-mise myocardial perfusion. Thus, these resistance vessels may have a distinctive role in the pathophysiology of graft injury, which may occur in advance of angiographic evidence of disease in the epicardial coronary arteries.
Recently, the endothelium has been recognized as being an important regulator of underlying vasomotor tone in both large and small coronary vessels (via release of endothelium-derived relaxing factor). It has also been shown to be capable of regulating the growth of underlying smooth muscle. 3 The endothelial cell is the first cell type encountered by the bloodborne cells of the host immune system. Thus, the small-vessel endothelium may have a unique role in transplant arteriosclerosis as an early target of immune injury. Potentially, both the proliferative response of vascular smooth muscle and intima (leading to occlusive disease and myocardial ischemia) and vasomotor response (leading to disordered blood flow regulation) may be affected, contributing to ischemic injury.
In humans, both atherosclerotic coronary disease and transplant arteriosclerosis impair large coronary artery vasodilator responses to endothelium-dependent agents.4,5 Fish et a15 used the endothelium-dependent vasodilator acetylcholine to show that epicardial coro-Definition of Clinical Factors Rejection: Active rejection7 (multifocal lymphocytic infiltration with associated myocyte necrosis) on biopsy at time of catheterization requiring specific antirejection therapy.
Pretransplant history of ischemic heart disease: History of significant epicardial coronary stenoses on catheterization before transplantation (at least one >70%-diameter stenosis) Total episodes of rejection: Total number of episodes of biopsy-documented rejection requiring specific antirejection therapy from time of transplantation to time of study Mean total cholesterol: Average of all monthly total cholesterol levels (mg/dl) analyzed in the clinical chemistry laboratory at Brigham and Women's Hospital (using the enzymatic-colorimetric method, Technicon SMAC System) since time of transplantation; when cholesterol levels were evaluated multiple times within the same month, the average of these levels was used as representative of that month. Mean cyclosporine level: Average of all trough cyclosporine levels (ng/ml) ( We investigated the hypotheses that 1) the coronary microvascular endothelium is functionally damaged in cardiac transplant patients, and 2) this functional impairment worsens as graft arteriosclerosis progresses.
We tested these hypotheses by evaluating coronary blood flow (CBF) responses to the essentially endothelium-independent dilator adenosine and to the endothelium-dependent vasodilator acetylcholine and correlated this measure of functional endothelial integrity with clinical and laboratory factors.
Methods

Patient Population
Twenty-nine transplant patients underwent 40 studies at 1 (n=17), 2 (n=10), and 3 (n-13) years after transplantation, and results were compared with results of seven nontransplanted controls undergoing diagnostic catheterization for atypical chest pain. No 
Estimates of CBF Changes
Relative changes in CBF were measured by multiplying changes in mean CBF velocity (as measured directly by the Doppler catheter) by changes in estimated vessel cross-sectional area (determined from the change in vessel diameter 2-4 mm distal to the catheter tip relative to control).
Statistical Analysis
Variations in hemodynamic parameters during the study and differences in dose-response curves to acetylcholine and adenosine were evaluated using repeated-measures ANOVA. Analysis of the association of clinical factors (transplant recipient age, total episodes of rejection, age of donor heart, sex, pretransplant history of ischemic heart disease, history of hypertension) and laboratory factors (active rejection, mean cholesterol level, mean cyclosporine level, arterial pressure, and heart rate) with the responses to drug infusions was performed using stepwise linear regression and repeated-measures ANOVA. Because results were similar when performing the statistical analysis with and without serially studied patients, the reported results include all studies. Statistical significance was assumed if the null hypothesis (two-tailed where appropriate) could be rejected at the p=0.05 level. All data are expressed as mean±SEM.
Results
Baseline Clinical and Hemodynamic Characteristics
Forty studies were performed in 29 transplanted patients (mean age, 42+2 years; age range, 20-63 years; four were female). Seventeen studies were done in patients 1 year after transplantation (Yr 1 TX), 10 were performed 2 years after transplantation (Yr 2 TX), and 13 were performed 3 years after transplantation (Yr 3 TX). Eleven patients were studied twice (five at years 1 and 2, five at years 2 and 3, and one at years 1 and 3). Ten had a pretransplant history of ischemic heart disease. Only two had no history of hypertension, and only four had active rejection on biopsy at time of study. Mean number of rejection episodes since transplantaranged from 148 to 333 mg/dl (only two patients had mean total cholesterol levels <200 mg/dl) with a group mean cholesterol level of 258±+6 mg/dl. A total cholesterol level was available for 100% of the months after transplantation. Mean trough cyclosporine levels ranged from 99 to 261 ng/ml with a group mean cyclosporine level of 165±7 ng/ml. A trough cyclosporine level was available for 85% of the months after transplantation. Mean age of the donor heart was 24±1 years (range, 16-41 years).
Mean age of control patients was 40±2 years (range, 31-48 years); one was female. Clinical, echocardiographic, and hemodynamic data for these patients have been previously reported.6 These patients had atypical chest pain, normal wall thickness and ventricular function on echocardiogram, and angiographically normal coronary arteries at the time of catheterization.
In addition to the 40 studies in 29 patients, we were unable to assess microvascular responses to acetylcholine in 13 transplant patients because of flow-limiting epicardial constriction to acetylcholine. Clinical and laboratory evaluations revealed these patients to be similar to our study population. This group had a mean age of 39±4 years (age range, 16-60 years); five were female. Two had a pretransplant history of ischemic heart disease. Twelve had a history of hypertension. Two had rejection on biopsy obtained at the time of catheterization. Mean total episodes of rejection since transplantation were 3.9±0.5. Group mean total cholesterol level was 252±12 mg/dl, and group mean trough cyclosporine level was 160±12 ng/ml. Mean age of the donor heart was 22±2 years (range, 16-35 years). Five were Yr 1 TX, three were Yr 2 TX, and five were Yr 3 TX. One was a year-3 study of a patient who had been studied in years 1 and 2 and subsequently developed significant epicardial arteriosclerosis. One was a year-2 study of a patient who had been studied in year 1 and subsequently developed significant epicardial arteriosclerosis.
Echocardiographic evaluation of transplanted patients (Table 1) 35±+ 12%, and 57±+9% (representing acetylcholine 10M /peak adenosine, acetylcholine 10`7 M/peak adenosine, and acetylcholine 10-6 M/peak adenosine, respectively)] and Yr 1 TX (3+3%, 17+6%, and 56+10%) (p=NS) had similar measures of endothelium-dependent vasodilation. Yr 2 TX had a diminishing response (4±1%, 18+4%, and 47±12%) and Yr 3 TX (3±3%, 8+4%, and 29±9%) had a significantly lower measure FIGURE 3. Plot ofendothelium-dependent coronary flow responses expressed as a ratio of acetylcholine dose response to adenosine peak response. The endothelium-dependent flow response was significantly impaired in year 3 transplantpatients versus controls (p=0. 03 by repeated-measures ANOVA). 8 7 6 ACETYLCHOLINE DOSE (-LOG M) Of the patients undergoing serial studies, there was a trend toward a decreased endothelium-dependent flow response (peak acetylcholine/peak adenosine response, 72+21% to 36+14% in patients studied in years 1 and 2, and 41+20% to 32+36% in patients studied in years 2 and 3) (Figure 4 ), although these differences did not reach statistical significance.
Predictors of the Endothelium-Dependent Flow Response
By repeated-measures ANCOVA and stepwise linear regression, mean trough cyclosporine level (r=0.67, p=0.004) and transplant recipient age (r=0.51, p=0.004) were the only correlates of the endotheliumdependent flow response (peak acetylcholine response/ peak adenosine response) among all factors analyzed (donor age, sex, pretransplant history of ischemic heart disease, years after transplantation, active rejection, total episodes of rejection, history of hypertension, arterial pressure at time of study, and mean cholesterol level). A preserved endothelium-dependent response correlated with increased cyclosporine levels and increased transplant recipient age. After exclusion of active rejection on biopsy, history of hypertension and hypercholesterolemia, cyclosporine level, and transplant recipient age continued to be the only significant predictors of the endothelium-dependent response. Univariately, the correlation of cyclosporine to the endothelium-dependent flow response was similar from year to year, indicating that this association was not dependent on years after transplantation. Although only 85% of the months had cyclosporine levels available for analysis, the differences in cyclosporine levels between years and the correlation of cyclosporine levels with the microvascular endothelial response cannot be explained by the percentage of data missing (p=0.24).
The slope of each patient's endothelium-dependent flow response was calculated to allow graphic representation of the relation of cyclosporine to microvascular endothelial function ( Figure 5) . A more positive slope (increasing flow with increasing acetylcholine dose) reflects microvascular dilation. Again, a preserved endothelium-dependent response correlated with increased cyclosporine levels (r=0.52,p<0.05).
Pathological Evaluation
In one patient who died as a result of ischemic left ventricular dysfunction 10 months after his year 3 study (3 years and 10 months after transplant), pathological evaluation revealed marked intimal proliferation with near-obliteration of the vessel lumen consistent with graft arteriosclerosis (Figure 6 ). His microvascular endothelium-dependent vasodilator response was impaired in his year 3 study (50% increase in CBF in response to acetylcholine 10-6 M; only 24% of his flow response was attributable to endothelium-dependent vasodilation).
Discussion
In a cohort of cardiac transplant patients, we assessed the functional integrity of the coronary microvasculature. By recording CBF at constant pressure, we measured changes of small-vessel resistance -the microvascular vasomotor response. The responses to the endothelium-dependent vasodilator acetylcholine demonstrated a loss of normal microvascular endotheliumdependent vasodilation over time. A trend suggesting progressive impairment of the vasodilator response to adenosine was also observed. However, in normalizing the acetylcholine response by the adenosine response in each case, we found the endothelium-dependent vaso- In this study, we found a positive correlation of cyclosporine levels with microvascular endothelium-dependent vasodilation. The effect of cyclosporine on endothelial cell function is controversial. Bossaller et al,27 in the nontransplanted rat aorta, found that cyclosporine acutely impairs endothelium-dependent vasodilation and decreases prostacyclin production. Others have seen no effect of cyclosporine on the ability of the endothelium to produce and release endothelium-derived relaxing factor.28 To our knowledge, no study has evaluated the effect of cyclosporine on endotheliumdependent vasodilation and endothelium-derived relaxing factor production in vessels damaged by graft arteriosclerosis. We speculate that our observed association of increased cyclosporine levels with preserved microvascular endothelial function may be a direct result of cyclosporine's suppression of the immune process on the endothelial surface of the graft. It is equally possible that this is an association of two pathophysiologically unrelated factors. Further investigation of the effects of cyclosporine on endothelial function in the transplant model is warranted.
The role of cyclosporine as an inhibitor or promoter of graft arteriosclerosis is also controversial. Zusman et al,29 in a study of patients 3-4 years after transplantation, found that 72% of cyclosporine-treated patients were free of graft arteriosclerosis, whereas only 61% of conventionally treated (azathioprine and prednisone) patients had no graft arteriosclerosis. Lurie et al,20 in a rat heart transplant model, found that cyclosporine effectively prevented the development of graft arteriosclerosis. However, in rat aortic allografts, cyclosporine treatment produces "endothelialitis" and accelerated arteriosclerosis. 30 Transplant recipient age also was positively correlated with the microvascular endothelial vasodilator response. Although this association is weaker than that of cyclosporine with endothelium-mediated vasodilation, one potential explanation for this finding could relate to changes in the immune response with age. We can only speculate that older transplant recipients with less immunocompetence would suffer less graft microvascular immune-mediated damage and consequently have more preserved vasodilator responses to acetylcholine. We found no other clinical or laboratory factors that correlated with the microvascular endothelial vasodilator response.
Study Limitations
Studies in an additional 13 patients could not be completed due to flow-limiting large-vessel constriction in response to acetylcholine; comparison of their clinical variables with those of the studied population did not show evident bias represented by their exclusion.
Because few patients had active rejection or diabetes mellitus but the majority had elevated cholesterol levels and hypertension, our analysis was necessarily less sensitive to the correlation of these factors with the microvascular endothelial vasodilator response. We are continuing to examine these correlates in extended follow-up of our growing cohort of transplant patients.
This study does not address mechanisms of endothelial dysfunction in the transplant population. The abnormality we describe may not be due solely to impaired endothelium-mediated vasodilation. Endotheliumderived relaxing factor release, free radical inactivation of endothelium-derived relaxing factor, or one of many other potential mechanisms observed in experimental models of disease may account for this abnormality. [31] [32] [33] In addition, we cannot be sure whether these altered responses to acetylcholine represent altered maximal responses or altered vessel wall sensitivity, but either case is consistent with endothelial dysfunction.
In summary, we have demonstrated that microvascular endothelium-dependent vasodilation diminishes over time in cardiac transplant patients. This may reflect both primary deterioration of endothelial function and underlying vasomotor insensitivity as graft arteriosclerosis progresses. Loss of endothelium-mediated control of CBF may contribute to progressive ischemia and myocardial damage in the transplanted heart. Possibly, other functions of the endothelium (e.g., maintenance of an antithrombotic surface, growth factor production) may also be altered by graft arteriosclerosis, thereby contributing further to the process.
Considered together, our results raise expectations that therapies directed toward the protection of the microvessels, the endothelium in particular, from immune injury may beneficially alter the process of microvascular transplant arteriosclerosis. This process may be monitored by serial measurement of endothelium-dependent vasodilation, which in the future may provide a means of detecting clinically important transplant arteriosclerosis at an early stage. Improved understanding of microvascular endothelium-dependent function and the immune mechanisms that affect it may permit more specific and successful therapies for protection of the transplanted heart from ischemic damage and for improved long-term survival.
